Sarah Noonberg

Dr. Noonberg was appointed to the board of directors in May 2023.

Dr. Noonberg is a physician-scientist with a diverse background in translational science, clinical development, medical affairs, and corporate governance. She has significant experience designing and leading rare disease programs from discovery to global regulatory approvals and commercialization. Dr. Noonberg currently serves as the Chief Medical Officer of Metagenomi, a privately held genomics company, where she is advancing its gene editing technology platform toward the clinic. She previously served as Chief Medical Officer of Maze Therapeutics, Nohla Therapeutics and Prothena Biosciences and prior to that, held clinical development executive leadership roles at BioMarin and at Medivation. Her industry experience is complemented by more than 10 years of experience treating patients as a hospitalist physician.

She cur­rent­ly serves on the Board of Direc­tors at Pro­tag­o­nist Ther­a­peu­tics and Neoleukin Ther­a­peu­tics. She trained in inter­nal med­i­cine at Johns Hop­kins Hos­pi­tal, received an M.D. from the Uni­ver­si­ty of Cal­i­for­nia, San Fran­cis­co, a Ph.D. in bio­engi­neer­ing from the Uni­ver­si­ty of Cal­i­for­nia, Berke­ley, and a bachelor’s degree in engi­neer­ing sci­ence from Dart­mouth College.